ScripGalapagos revealed its second leadership transition in as many weeks on 22 April, reporting that CEO Paul Stoffels plans to retire from the company upon the appointment of a new chief executive, who w
ScripGilead Sciences has worked for decades to build a dominant presence in HIV treatment and prevention, but the company is only years into its buildout of an oncology portfolio, with even more work to do
ScripAfter years of declining investor confidence in its business model, Galapagos is to start afresh by splitting in two and resetting its failed in-licensing deal with Gilead . The Belgium-based biote
ScripGalapagos is to launch its first US-based clinical trial of its point-of-care CAR-T technology, which it hopes can be a game-changer in oncology. The novel CAR-T technology has been Galapagos’s brigh